Real-World watch: tracking a rare liver disease Drug's Long-Term impact
NCT ID NCT07185919
Summary
This study is collecting long-term information from about 10 people in South Korea who are already taking odevixibat (Bylvay) for a rare liver disease called PFIC. The goal is to see how well the medicine works and how safe it is over many years in everyday life. It will track health events and survival, but it does not test a new treatment—it observes people using an already-approved drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.